Securities

Homyk v. ChemoCentryx Securities Litigation

ChemoCentryx, Inc.

Investors who purchased ChemoCentryx stock Nov 2019-May 2021 can claim they were harmed by false statements about the drug avacopan and FDA communications. Settlement reached without admission of wrongdoing.

Total fund

$69M

Estimated payout

Pro-rata share of the Net Settlement Fund under the Plan of Allocation, based on documented ChemoCentryx stock purchases/losses during the Class Period. The exact per-claimant amount cannot be determined until the Court approves the Settlement and a plan of allocation and claims processing completes.

Deadline

Oct 1, 2026

Affected class

~35,220 potential Class Members were mailed notice in 2024

Administrator

Kroll Settlement Administration

Proof required

Yes

Who may qualify

Investor who purchased ChemoCentryx common stock Nov 26, 2019 through May 6, 2021 and suffered damages.

How to claim

This claim is publicly available and free to file yourself directly with the settlement administrator. Read the official eligibility rules and deadline before filing - they are the source of truth. PendingMoney can find, fill, and track it for you, but you can always do it on your own.

View official requirements on chemocentryxsecuritieslitigation.com

Not sure if this one - or others - may be waiting in your name? Run a free 2-minute check.

Find My Pending Money

Eligibility and payouts are not guaranteed and are decided by the settlement administrator, not PendingMoney. PendingMoney is not a law firm and does not provide legal advice. Available to U.S. residents only.

← Back to the Settlement Library